Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock unit (RSU) awards to three new non-executive employees. The awards, totaling 2,100 shares of common stock, were issued under the company's 2024 Inducement Plan on July 1, 2025.
The RSUs will vest over four years in equal annual installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new hires who were not previously Praxis employees.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi del sistema nervoso centrale, ha assegnato premi in azioni vincolate (RSU) a tre nuovi dipendenti non esecutivi. I premi, per un totale di 2.100 azioni ordinarie, sono stati emessi ai sensi del Piano di Incentivazione 2024 della societ脿 il 1掳 luglio 2025.
Le RSU matureranno in quattro anni con rate annuali uguali, subordinatamente alla permanenza in servizio. Questi premi sono stati concessi in conformit脿 alla Regola 5635(c)(4) del Nasdaq come incentivi per nuovi assunti che non erano precedentemente dipendenti di Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), una empresa biofarmac茅utica en etapa cl铆nica enfocada en trastornos del sistema nervioso central, ha otorgado premios en unidades de acciones restringidas (RSU) a tres nuevos empleados no ejecutivos. Los premios, que suman 2,100 acciones comunes, fueron emitidos bajo el Plan de Inducci贸n 2024 de la compa帽铆a el 1 de julio de 2025.
Las RSU se consolidar谩n durante cuatro a帽os en cuotas anuales iguales, condicionadas a la continuidad del empleo. Estas concesiones se realizaron conforme a la Regla 5635(c)(4) de Nasdaq como premios de inducci贸n para nuevas contrataciones que no eran empleados anteriores de Praxis.
Praxis Precision Medicines (NASDAQ: PRAX)電� 欷戩稊鞁犼步瓿� 歆堩櫂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 靹� 氇呾潣 鞁犼窚 牍勳瀯鞗� 歆侅洂鞐愱矊 鞝滍暅 欤检嫕 雼渼(RSU) 靸侅棳毳� 攵�鞐枅鞀惦媹雼�. 齑� 2,100欤�鞚� 氤错喌欤缄皜 2025雲� 7鞗� 1鞚� 須岇偓鞚� 2024雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 氚滍枆霅橃棃鞀惦媹雼�.
搁厂鲍电� 4雲勳棎 瓯胳硱 攴犽摫 鞐瓣皠 攵勴暊搿� 氩犾姢韺�霅橂┌, 瓿勳啀 瓿犾毄 靸來儨毳� 鞙犾頃橂姅 瓴冹潉 臁瓣贝鞙茧 頃╇媹雼�. 鞚� 靸侅棳電� 鞚挫爠鞐� Praxis 歆侅洂鞚� 鞎勲媹鞐堧崢 鞁犼窚 毂勳毄鞛愲ゼ 鞙勴暅 鞙犾澑 靸侅棳搿滌劀 Nasdaq 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Praxis Precision Medicines (NASDAQ : PRAX), une entreprise biopharmaceutique en phase clinique sp茅cialis茅e dans les troubles du syst猫me nerveux central, a attribu茅 des attributions d鈥檜nit茅s d鈥檃ctions restreintes (RSU) 脿 trois nouveaux employ茅s non cadres. Ces attributions, totalisant 2 100 actions ordinaires, ont 茅t茅 茅mises dans le cadre du Plan d鈥橧ncitation 2024 de la soci茅t茅 le 1er juillet 2025.
Les RSU seront acquises sur une p茅riode de quatre ans par versements annuels 茅gaux, sous r茅serve de la poursuite de l鈥檈mploi. Ces attributions ont 茅t茅 effectu茅es conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq en tant que r茅compenses d鈥檌ncitation pour les nouvelles recrues qui n鈥櫭﹖aient pas auparavant employ茅es par Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Erkrankungen des zentralen Nervensystems, hat drei neuen nicht gesch盲ftsf眉hrenden Mitarbeitern Restricted Stock Unit (RSU)-Zuwendungen gew盲hrt. Die Zuwendungen in H枚he von insgesamt 2.100 Stammaktien wurden am 1. Juli 2025 im Rahmen des Inducement-Plans 2024 des Unternehmens ausgegeben.
Die RSUs werden 眉ber vier Jahre in gleichen j盲hrlichen Raten unverfallbar, vorausgesetzt, die Besch盲ftigung besteht weiterhin. Diese Zuwendungen erfolgten gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz f眉r neue Mitarbeiter, die zuvor nicht bei Praxis besch盲ftigt waren.
- None.
- None.
BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis鈥� Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees鈥� entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals鈥� entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee鈥檚 continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽聽and follow us on聽,听听补苍诲听.
Contacts: Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
What type of stock awards did Praxis Precision Medicines (PRAX) grant on July 1, 2025?
How will the PRAX restricted stock units vest for the new employees?
What is the purpose of Praxis Precision Medicines' 2024 Inducement Plan?
What is Praxis Precision Medicines' main business focus?
